ASH Poster Walks
Moderator:
Disclosures:
No relevant conflicts of interest to declare.
Panelists:
Rodrigo T. Calado, MD, PhD, University of Sao Paulo
,
Antonio Risitano, MD, PhD, University of Naples
,
Steven Z. Pavletic, MD, MS, Immune Deficiency Cellular Therapy Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health
,
Noelle V. Frey, MD, MS, Hospital of the University of Pennsylvania
,
Loretta J. Nastoupil, MD, The University of Texas MD Anderson Cancer Center
,
Jie Wang, MD, MS, Duke University
,
Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center
,
Viktoria Blumenberg, MD, Department of Medicine III, University Hospital, LMU Munich
,
Michael B. Jordan, MD, Division of Immunobiology, Cincinnati Children's Hospital Medical Center
,
Federico Simonetta, MD, PhD, Stanford University
,
Peter Hillmen, MBChB, FRCP, FRCPath, PhD, St. James's University Hospital
and
Miguel-Angel Perales, MD, Memorial Sloan Kettering Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
The following abstracts will be featured during this session:
A Novel Approach for Treatment of T-Cell Malignancies: Targeting T-Cell Receptor Vβ Families, Jie Wang
High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics, Jordan Gauthier
Antibiotic Therapy and Low Gut Microbiome Diversity Is Associated with Decreased Response and High Toxicity in BCP-ALL and DLBCL Patients after Treatment with CD19. CAR T-Cells, Viktoria Blumenberg
Sensitivity Analysis of Overall Response Rate (ORR) with Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis (HLH), Michael Jordan
Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet, Federico Simonetta
Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria, Peter Hillmen